

wherein C is a carbon atom or lower alkyl chain, optionally substituted with one or more -OH groups;


B is a single bond, a double bond or a triple bond;

D is a chain having from 1 to 10 carbon atoms, optionally substituted with one or more -OH groups; and

A1 cont.
R₂ is H; [or] a phenyl group having none, one or more substituents selected from the group consisting of C₁-C₅ alkyl groups, C₁-C₅ haloalkyl groups, C₁-C₄ alkoxy groups, C₁-C₄ haloalkoxy groups, trifluoromethyl groups, C₁-C₃ aliphatic acylamino groups, nitro groups, halogen atoms, and phenyl groups; [or] an aromatic heterocyclic group having 5-6 ring atoms; or a cycloalkane or a cycloalkene with 3-7 carbon atoms in the ring, optionally substituted with lower alkyl groups with 1-5 carbon atoms;


or a [and the] pharmacologically acceptable acid addition salt [salts] thereof[, in association with a topical pharmaceutical carrier].

5 (Amended) A method for the conversion of vellus hair or intermediate hair to growth as terminal hair comprising the application to mammalian skin at the locale of vellus hair of an effective amount of a prostaglandin [PGA, PGE or] PGF compound wherein the alpha chain of the compound has the formula:



in which R₁ is H or an alkyl group having 1 to 10 carbon atoms, especially 1 to 6 atoms, for instance methyl, ethyl, propyl, isopropyl, butyl, isobutyl, neopentyl or benzyl or a derivative giving the final substance equivalent properties as a hair growth stimulating agent; and

the omega chain of the compound has the formula:



wherein C is a carbon atom or lower alkyl chain, optionally substituted with one or more -OH groups;


B is a single bond, a double bond or a triple bond;

D is a chain having from 1 to 10 carbon atoms, optionally substituted with one or more -OH groups; and

A2 cont
R₂ is H; [or] a phenyl group having none, one or more substituents selected from the group consisting of C₁-C₅ alkyl groups, C₁-C₅ haloalkyl groups, C₁-C₄ alkoxy groups, C₁-C₄ haloalkoxy groups, trifluoromethyl groups, C₁-C₃ aliphatic acylamino groups, nitro groups, halogen atoms, and phenyl groups; [or] an aromatic heterocyclic group having 5-6 ring atoms; or a cycloalkane or a cycloalkene with 3-7 carbon atoms in the ring, optionally substituted with lower alkyl groups with 1-5 carbon atoms;

or a [and the] pharmacologically acceptable acid addition salt [salts] thereof], in association with a topical pharmaceutical carrier].


A3
~~13~~⁹. (Amended) A method for stimulating hair follicles to increase [enhance] hair growth and one or more properties selected from the group consisting of luster, sheen, brilliance, gloss, glow, shine or patina of hair associated with the follicles, comprising the application to mammalian skin at the locale of the follicles of an effective amount of a prostaglandin [PGA, PGE or] PGF compound wherein the alpha chain of the compound has the formula:



LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

in which R₁ is H or an alkyl group having 1 to 10 carbon atoms, especially 1 to 6 atoms, for instance methyl, ethyl, propyl, isopropyl, butyl, isobutyl, neopentyl or benzyl or a derivative giving the final substance equivalent properties as a hair growth stimulating agent; and

the omega chain of the compound has the formula:



wherein C is a carbon atom or lower alkyl chain, optionally substituted with one or more -OH groups;

B is a single bond, a double bond or a triple bond;

D is a chain having from 1 to 10 carbon atoms, optionally substituted with one or more -OH groups; and

R₂ is H; [or] a phenyl group having none, one or more substituents selected from the group consisting of C₁-C₅ alkyl groups, C₁-C₅ haloalkyl groups, C₁-C₄ alkoxy groups, C₁-C₄ haloalkoxy groups, trifluoromethyl groups, C₁-C₃ aliphatic acylamino groups, nitro groups, halogen atoms, and phenyl groups; [or] an aromatic heterocyclic group having 5-6 ring atoms; or a cycloalkane or a cycloalkene with 3-7 carbon atoms in the ring, optionally substituted with lower alkyl groups with 1-5 carbon atoms;

or a [and the] pharmacologically acceptable acid addition salt [salts] thereof], in association with a topical pharmaceutical carrier].

REMARKS

Claims 1-13 were pending in the application. By the foregoing amendments, Claims 1-4 have been cancelled without acquiescence in the Examiner's rejection of these claims or prejudice to the applicant's right to pursue the subject matter of these claims in a separate application. Claims 5, 9 and 13 have been amended to more distinctly claim the subject matter